Company > Strategy
Acacia Pharma aims to become a leader in supportive care, providing products for hospital-based anaesthetists, and their surgical teams, and hospital and clinic-based oncologists. The key elements of this strategy are:
- Complete the development of and regulatory filing for the Group’s lead supportive care product candidates, BAREMSIS™ (APD421) for the prophylaxis and treatment of PONV, and APD403 for the management of CINV;
- Independently commercialise the Group’s supportive care products in the US through its own sales and marketing infrastructure;
- Establish strategic partnerships for the commercialisation of its products with companies outside the US that have expertise, sales and marketing infrastructure, initially focusing on the major pharmaceutical markets, e.g. Europe; and
- Exploit the Group’s future commercial infrastructure through creating in-house or acquiring complementary products.